InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
58,105.25
(
0.37%
)
Post# of 252588
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: microcapfun post# 55656

Monday, 12/17/2007 12:41:59 PM

Monday, December 17, 2007 12:41:59 PM

Post# of 252588
Ablynx Reports Positive Phase-1 Results for Anti-Thrombotic Nanobody®

http://biz.yahoo.com/iw/071217/0340793.html

>>
Monday December 17, 12:17 pm ET

GHENT, BELGIUM--(MARKET WIRE)--Dec 17, 2007 -- Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today reported the final, positive results from a Phase I study of its lead development programme, ALX-0081. The results of the double-blind, placebo controlled study in 40 healthy male volunteers show that ALX-0081, an anti-thrombotic therapeutic, was safe and well tolerated at all doses tested, with no dose limiting toxicities or serious adverse events.

ALX-0081, generated through Ablynx's in-house discovery platform, is a novel "first-in-class" therapeutic Nanobody® targeting von Willebrand Factor (anti-vWF). It is being developed to reduce the risk of thrombosis in patients with acute coronary syndrome (ACS) and thrombotic thrombocytopenic purpura (TTP). Following these positive Phase I results, Ablynx will now progress ALX-0081 to a multi-dose study in 2008.

In the study, treatment with the Nanobody® did not result in detectable immunogenicity. The study suggests that ALX-0081 adopts at least the plasma half-life of the target, von Willebrand Factor. The expected anti-thrombotic activity was shown with a biomarker in all volunteers receiving at least 2 mg of ALX-0081, indicating the high potency of the drug. ALX-0081's pharmacological activity, based on a single injection, started at the lowest dose of 2 mg and reached a maximum duration of 12 hours at a dose of 12 mg.

Edwin Moses, CEO and Chairman said: "We are extremely pleased with these positive safety results and demonstration of the high potential potency of ALX-0081, our first Nanobody® in clinical development. In addition, ALX-0081 has been progressed from discovery to completion of Phase I in just over three years, demonstrating the speed at which our discovery platform can generate a novel therapeutic. Based on these positive data, we are looking forward to initiating our discussions with the regulatory authorities this year and embarking on our next clinical study in 2008 in order to progress programmes in acute coronary syndrome and TTP."
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up